Disease The intractable diseases designated by MHLW, Japan
Diseases : 338 - Clinical trials : 34,520 / Drugs : 19,957 - ( DrugBank : 2,195 ) / Drug target genes : 613 - Drug target pathways : 297
Showing 1 to 10 of 338 diseases
ID | Disease name [Group] | Clinical trial Phase 1 / 2 / 3 / 4 | Drug [ DrugBank ] | Target gene Target pathway | Domestic patients Med expenses recipients (FY2022) | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Spinal and bulbar muscular atrophy [Neu] 💬 "Spinobulbar muscular atrophy", "SBMA", "Kennedy disease", "Kennedy-Alter-Sung syndrome" | 18 18 trials | 1 / 10 / 2 / 1 💬 | 15 15 drugs [ 8 8 drugs ] | 10 10 genes 17 pathways | 1697 1,697 patientsAge distribution ![]() 1. Spinal and bulbar muscular atrophy
| ||||||||||||||||||||
2 | Amyotrophic lateral sclerosis [Neu] 💬 "ALS" | 645 645 trials | 227 / 290 / 231 / 26 💬 | 589 589 drugs [ 163 163 drugs ] | 150 150 genes 225 pathways | 9765 9,765 patientsAge distribution ![]() 2. Amyotrophic lateral sclerosis
| ||||||||||||||||||||
3 | Spinal muscular atrophy [Neu] 💬 "Myelopathic muscular atrophy", "Spinal muscular atrophy type I", "SMA I", "Werdnig-Hoffman disease", "Spinal muscular atrophy type II", "SMA II", "Dubowitz disease", "Spinal muscular atrophy type III", "SMA III", "Kugelberg-Welander disease", "Spinal muscular atrophy type IV", "SMA IV" "Myelopathic muscular atrophy", "Spinal muscular atrophy type I", "SMA I", "Werdnig-Hoffman disease" ... | 237 237 trials | 106 / 117 / 116 / 28 💬 | 123 123 drugs [ 29 29 drugs ] | 51 51 genes 75 pathways | 955 955 patientsAge distribution ![]() 3. Spinal muscular atrophy
| ||||||||||||||||||||
4 | Primary lateral sclerosis [Neu] 💬 "PLS" | 5 5 trials | 2 / 2 / 0 / 1 💬 | 13 13 drugs [ 6 6 drugs ] | 13 13 genes 25 pathways | 146 146 patientsAge distribution ![]() 4. Primary lateral sclerosis
| ||||||||||||||||||||
5 | Progressive supranuclear palsy [Neu] 💬 "PSP" | 89 89 trials | 45 / 42 / 9 / 6 💬 | 107 107 drugs [ 40 40 drugs ] | 65 65 genes 108 pathways | 12830 12,830 patientsAge distribution ![]() 5. Progressive supranuclear palsy
| ||||||||||||||||||||
6 | Parkinson disease [Neu] 💬 "Disease Parkinson's" | 2,307 2,307 trials | 810 / 703 / 607 / 290 💬 | 2,007 2,007 drugs [ 349 349 drugs ] | 188 188 genes 199 pathways | 143267 143,267 patientsAge distribution ![]() 6. Parkinson disease
| ||||||||||||||||||||
7 | Corticobasal degeneration [Neu] 💬 "Corticobasal syndrome", "CBD" | 16 16 trials | 5 / 3 / 1 / 0 💬 | 28 28 drugs [ 13 13 drugs ] | 9 9 genes 38 pathways | 4428 4,428 patientsAge distribution ![]() 7. Corticobasal degeneration
| ||||||||||||||||||||
8 | Huntington disease [Neu] 💬 "Huntington chorea" | 242 242 trials | 111 / 134 / 50 / 13 💬 | 205 205 drugs [ 62 62 drugs ] | 85 85 genes 159 pathways | 892 892 patientsAge distribution ![]() 8. Huntington disease
| ||||||||||||||||||||
9 | Neuroacanthocytosis [Neu] 💬 "Choreoacanthocytosis", "Chorea-acanthocytosis", "Levine-Critchley syndrome", "McLeod syndrome", "Huntington disease-like 2", "HDL2", "Pantothenate kinase-associated neurodegeneration", "PKAN", "Hallervorden-Spatz syndrome" "Choreoacanthocytosis", "Chorea-acanthocytosis", "Levine-Critchley syndrome", "McLeod syndrome", "Hu ... | 0 - | 0 - | 0 - | 36 36 patientsAge distribution ![]() 9. Neuroacanthocytosis
| ||||||||||||||||||||
10 | Charcot-Marie-Tooth disease [Neu] 💬 "CMT", "Charcot-Marie-Tooth disease type 1", "CMT1", "Demyelinating CMT", "Charcot-Marie-Tooth disease type 2", "CMT2", "Axonal CMT", "Intermediate Charcot-Marie-Tooth disease", "CMT-I", "Intermediate CMT" "CMT", "Charcot-Marie-Tooth disease type 1", "CMT1", "Demyelinating CMT", "Charcot-Marie-Tooth disea ... | 41 41 trials | 25 / 17 / 24 / 4 💬 | 46 46 drugs [ 9 9 drugs ] | 11 11 genes 15 pathways | 845 845 patientsAge distribution ![]() 10. Charcot-Marie-Tooth disease
|